JoinClinicalTrials.com

Results

Hot

Post your clinical trial on JoinClinicalTrials.com

Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

• Safety Follow-up Study in Subjects With Silicone Gel-filled Breast Implants as Compared Both to Saline-filled Breast Implants and to National Norms

  NCT00443274

  Condition:   Breast Implant
  Interventions:   Other: NBIR Placeholder;   Device: 410 Arm;   Device: BIFs
  Sponsor:   Allergan
  Recruiting
• Comparison Between iLux and LipiFlow in the Treatment of Meibomian Gland Dysfunction (MGD): A 12-month, Multicenter Study

  NCT03956225

  Conditions:   Meibomian Gland Dysfunction;   Evaporative Dry Eye Disease
  Interventions:   Device: iLux® system;   Device: LipiFlow® Thermal Pulsation System
  Sponsor:   Alcon Research
  Recruiting
• Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation

  NCT03930732

  Condition:   Chronic Obstructive Pulmonary Disease
  Interventions:   Drug: Dupilumab SAR231893;   Drug: Inhaled Corticosteroid;   Drug: Inhaled Long-Acting Beta Agonist;   Drug: Inhaled Long-Acting Muscarinic Antagonist;   Drug: Placebo
  Sponsors:   Sanofi;   Regeneron Pharmaceuticals
  Recruiting
• The INSPIRE-ASP UTI Trial

  NCT03697096

  Condition:   Urinary Tract Infection (UTI)
  Interventions:   Other: Routine Care;   Other: INSPIRE CPOE Smart Prompt
  Sponsors:   Harvard Pilgrim Health Care;   Hospital Corporation of America Healthcare (HCA);   University of California, Irvine;   University of Massachusetts, Amherst;   Brigham and Women's Hospital;   Centers for Disease Control and Prevention
  Recruiting
• The INSPIRE-ASP PNA Trial

  NCT03697070

  Condition:   Pneumonia
  Interventions:   Other: INSPIRE CPOE Smart Prompt;   Other: Routine Care
  Sponsors:   Harvard Pilgrim Health Care;   Hospital Corporation of America Healthcare (HCA);   University of California, Irvine;   University of Massachusetts, Amherst;   Brigham and Women's Hospital;   Centers for Disease Control and Prevention
  Recruiting
• GB001 in Adult Subjects With Moderate to Severe Asthma

  NCT03683576

  Condition:   Asthma
  Interventions:   Drug: GB001;   Drug: Placebo Oral Tablet
  Sponsor:   GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.
  Recruiting
• Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

  NCT03574597

  Conditions:   Overweight;   Obesity
  Interventions:   Drug: Semaglutide;   Drug: Placebo (semaglutide)
  Sponsor:   Novo Nordisk A/S
  Recruiting
• Inpatient, Dose-Ranging Study of Staccato Alprazolam in Epilepsy With Predictable Seizure Pattern

  NCT03478982

  Condition:   Epilepsy
  Interventions:   Drug: Staccato Alprazolam;   Drug: Placebos
  Sponsor:   EngageTherapeutics, Inc.
  Recruiting
• Study to Assess Outcomes in Women Undergoing Either Hysteroscopic Sterilization (Essure®) or Laparoscopic Tubal Sterilization

  NCT03127722

  Condition:   Contraception
  Interventions:   Procedure: Blood draw;   Device: ESSURE (BAY1454032);   Procedure: Laparoscopic tubal sterilization
  Sponsor:   Bayer
  Recruiting
• Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency

  NCT03037931

  Conditions:   Heart Failure;   Iron-deficiency
  Interventions:   Drug: Ferric carboxymaltose;   Drug: Placebos
  Sponsors:   American Regent, Inc.;   Duke Clinical Research Institute
  Recruiting
• Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial

  NCT02089217

  Condition:   Carotid Stenosis
  Interventions:   Procedure: Carotid endarterectomy (CEA);   Device: Carotid Stenting (CAS);   Other: Intensive Medical Management - no CEA;   Other: Intensive Medical Management - no CAS
  Sponsors:   Thomas G. Brott, M.D.;   National Institute of Neurological Disorders and Stroke (NINDS)
  Recruiting
• A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

  NCT01848561

  Condition:   Ulcerative Colitis (UC)
  Intervention:  
  Sponsor:   AbbVie
  Recruiting
• Psoriasis Longitudinal Assessment and Registry (PSOLAR)

  NCT00508547

  Conditions:   Psoriasis;   Arthritis, Psoriatic
  Interventions:   Biological: Ustekinumab;   Biological: Biological therapies other than infliximab, ustekinumab and guselkumab;   Drug: Conventional systemic agents;   Biological: Infliximab;   Biological: Guselkumab
  Sponsor:   Janssen Scientific Affairs, LLC
  Recruiting
• CLUSTER Trial for Outbreak Detection and Response

  NCT04053075

  Condition:   Cluster Detection
  Interventions:   Other: Routine cluster detection;   Other: Enhanced cluster detection
  Sponsors:   Harvard Pilgrim Health Care;   Hospital Corporation of America (HCA) Healthcare;   Brigham and Women's Hospital;   University of California, Irvine;   Harvard School of Public Health;   Rush University;   Duke University;   University of Massachusetts, Amherst;   University of California, San Francisco;   Cook County Health & Hospitals System;   Centers for Disease Control and Prevention
  Recruiting
• A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma

  NCT03769090

  Condition:   Asthma
  Interventions:   Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg;   Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg;   Combination Product: Albuterol sulfate metered-dose inhaler 180 μg
  Sponsor:   Bond Avillion 2 Development LP
  Recruiting
• Once-Nightly Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy

  NCT02720744

  Conditions:   Excessive Daytime Sleepiness;   Cataplexy;   Narcolepsy
  Interventions:   Drug: Sodium Oxybate;   Drug: Placebo
  Sponsor:   Avadel
  Recruiting
• Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

  NCT01442194

  Condition:   Multiple Sclerosis
  Interventions:   Drug: other disease-modifying therapy;   Drug: Fingolimod
  Sponsor:   Novartis Pharmaceuticals
  Recruiting